伴侶動物術後疼痛管理治療市場規模、佔有率和成長分析：按藥物類別、動物種類、手術類型、最終用戶和地區分類－2026-2033年產業預測

2024 年，全球伴侶動物術後疼痛管理療法市場價值為 6.825 億美元，預計到 2025 年將成長至 2033 年的 12.854 億美元，預測期（2026-2033 年）複合年成長率為 7.23%。

全球伴侶動物術後疼痛管理市場的主要驅動力是寵物數量的成長、獸醫護理標準的提高以及製藥技術的不斷進步。該市場涵蓋多種治療方法，包括鎮痛藥、局部麻醉劑和抗發炎藥，使寵物能夠在術後快速無痛地康復。疼痛管理的改善不僅能帶來更好的臨床療效，增強飼主與獸醫之間的信任，還能促進獸醫院之間的差異化競爭，並增加市場需求。值得關注的趨勢包括：從傳統的鴉片類藥物和非類固醇抗發炎藥物轉向更具靶向性、長效的製劑，例如脂質體Bupivacaine和美洛昔康；以及採用多方面的疼痛管理策略。對緩釋技術和改良鎮痛方案的投入增加，尤其是在新興市場，帶來了巨大的成長機會。

全球伴侶動物術後止痛藥物市場成長要素

獸醫專業人士和寵物飼主對動物福利的日益關注，顯著提高了術後護理的期望，導致對有效鎮痛藥物的需求激增。隨著寵物舒適度和生活品質變得越來越重要，獸醫院擴大採用標準化的疼痛管理方案，並投資研發先進的止痛藥物。由於寵物飼主要求獸醫提供全面的疼痛管理解決方案，醫療保健機構和製造商也相應地加大投入，開發創新產品以滿足這些需求。這一趨勢不僅催生了更有效的疼痛管理方案，也促進了這些方案在獸醫院的推廣應用，從而推動了獸醫市場的顯著成長。

全球伴侶動物術後止痛藥物市場阻礙因素

法規結構的區域差異和核准標準的不一致，給希望在全球伴侶動物術後疼痛管理市場推出產品的製造商帶來了巨大挑戰。應對複雜的、特定於地區的要求——包括安全性和有效性方案、標籤要求以及上市後責任——增加了合規負擔，並阻礙了產品的及時上市。這種情況抑制了對新治療方法的投資，尤其對缺乏資源來妥善應對多重監管流程的小規模機構影響更大。因此，患者獲得先進疼痛管理方案的機會有限，導致這些治療方法在臨床上的應用延遲，並最終限制了整個市場的成長潛力。

全球伴侶動物術後疼痛管理治療市場趨勢

全球伴侶動物術後疼痛管理市場正呈現顯著的趨勢，即採用多方位止痛計畫。獸醫擴大將局部麻醉劑、非鴉片類藥物和各種治療方法結合，以最佳化術後鎮痛效果。這種轉變促進了綜合疼痛管理方案的製定，擺脫了對單一藥物的依賴，最終加快了動物的康復。獸醫各專科之間規範化的治療方案與密集培訓，推動了相關產品生產商的創新。因此，人們越來越重視開發多樣化的藥品和手術全期服務，以改善動物福利和臨床療效。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球伴侶動物術後止痛藥物市場規模：依藥物類別分類

• 非類固醇抗發炎藥（卡洛芬、美洛昔康）
• 鴉片類藥物（曲馬多、Butorphanol）
• 局部麻醉劑
• α-2促效劑
• 其他

全球伴侶動物術後鎮痛藥物市場規模：依動物種類分類。

• 狗
• 貓

全球伴侶動物術後止痛藥物市場規模：依手術類型分類

• 整形外科手術
• 軟組織手術
• 牙科手術

全球伴侶動物術後鎮痛藥物市場規模：依最終用戶分類。

• 動物醫院
• 動物診所
• 研究機構

全球伴侶動物術後止痛藥物市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Zoetis Inc.（Rimadyl, Galliprant）
• Elanco Animal Health（Onsior）
• Merck Animal Health
• Boehringer Ingelheim Animal Health
• Norbrook Laboratories
• Dechra Pharmaceuticals
• Vetoquinol SA
• Ceva Animal Health
• Phibro Animal Health
• Kindred Biosciences
• Aratana Therapeutics
• Pacira Biosciences
• Bimeda Animal Health
• Huvepharma
• Virbac SA
• Associated British Foods
• Nexcyon Pharmaceuticals
• VetDC Inc.
• Torigen Pharmaceuticals
• Phibro Animal Health

結論與建議

Global Companion Animal Postoperative Pain Management Therapeutics Market size was valued at USD 682.5 Million in 2024 and is poised to grow from USD 731.84 Million in 2025 to USD 1285.4 Million by 2033, growing at a CAGR of 7.23% during the forecast period (2026-2033).

The global companion animal postoperative pain management therapeutics market is primarily driven by increasing pet ownership, enhanced veterinary care standards, and ongoing pharmaceutical advancements. This market encompasses various modalities, including analgesics, local anesthetics, and anti-inflammatories, which facilitate quicker and less painful recovery for pets post-surgery. Enhanced pain management not only leads to improved clinical outcomes and fosters better relationships between pet owners and veterinarians but also elevates veterinary practice differentiation, heightening market demand. A notable trend is the shift from traditional opioids and NSAIDs to more targeted, long-acting formulations, including liposomal bupivacaine and meloxicam, as well as the adoption of multimodal pain strategies. Increased investment in sustained-release technologies and improved analgesia solutions presents substantial growth opportunities, particularly in developing markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Companion Animal Postoperative Pain Management Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Companion Animal Postoperative Pain Management Therapeutics Market Segments Analysis

Global companion animal postoperative pain management therapeutics market is segmented by drug class, animal, surgery type, end-user and region. Based on drug class, the market is segmented into NSAIDs (carprofen, meloxicam), opioids (tramadol, butorphanol), local anesthetics, alpha-2 agonists and others. Based on animal, the market is segmented into dogs and cats. Based on surgery type, the market is segmented into orthopedic surgery, soft tissue surgery and dental surgery. Based on end-user, the market is segmented into veterinary hospitals, veterinary clinics and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Companion Animal Postoperative Pain Management Therapeutics Market

The growing focus on animal welfare by veterinary professionals and pet owners has significantly heightened expectations surrounding postoperative care, leading to a surge in the demand for effective pain management therapeutics. Veterinary clinics are increasingly adopting standardized analgesia protocols and investing in advanced analgesics as the emphasis on comfort and quality of life for pets intensifies. As pet owners seek comprehensive pain management solutions from veterinarians, there is a corresponding rise in investment by both providers and manufacturers to develop innovative products that meet these needs. This trend not only results in the creation of more effective pain management options but also enhances their application in veterinary practices, fostering substantial growth within the veterinary market.

Restraints in the Global Companion Animal Postoperative Pain Management Therapeutics Market

Disparities in regional regulatory frameworks and inconsistent approval standards present significant challenges for manufacturers seeking to launch products in the Global Companion Animal Postoperative Pain Management Therapeutics market. Navigating the complexities of varying safety and efficacy protocols, labeling requirements, and post-approval responsibilities increases compliance burdens and hinders timely market introduction. This situation discourages investment in new treatments, particularly affecting smaller organizations that may lack the resources to adeptly handle multiple regulatory processes. Consequently, patients face a limited range of advanced pain management options, leading to slower clinic adoption of these therapies and ultimately constraining the overall growth potential of the market.

Market Trends of the Global Companion Animal Postoperative Pain Management Therapeutics Market

The Global Companion Animal Postoperative Pain Management Therapeutics market is witnessing a significant trend towards the adoption of multimodal analgesia. Veterinarians are increasingly implementing a combination of local anaesthetics, non-opioid medications, and various therapeutic approaches to optimize pain relief post-surgery. This shift encourages the development of comprehensive pain management plans that move away from singular medication reliance, thus promoting quicker recovery for animals. Enhanced standardization of protocols across veterinary specialties, alongside improved training, drives innovation from companies producing complementary products. As a result, there's a growing emphasis on developing diverse medications and perioperative services focused on elevating animal welfare and clinical outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Companion Animal Postoperative Pain Management Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• NSAIDs (Carprofen, Meloxicam)
• Opioids (Tramadol, Butorphanol)
• Local Anesthetics
• Alpha-2 Agonists
• Others

Global Companion Animal Postoperative Pain Management Therapeutics Market Size by Animal & CAGR (2026-2033)

• Market Overview
• Dogs
• Cats

Global Companion Animal Postoperative Pain Management Therapeutics Market Size by Surgery Type & CAGR (2026-2033)

• Market Overview
• Orthopedic Surgery
• Soft Tissue Surgery
• Dental Surgery

Global Companion Animal Postoperative Pain Management Therapeutics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Veterinary Hospitals
• Veterinary Clinics
• Research Institutes

Global Companion Animal Postoperative Pain Management Therapeutics Market Size & CAGR (2026-2033)

• North America (Drug Class, Animal, Surgery Type, End-User)
  • US
  • Canada
• Europe (Drug Class, Animal, Surgery Type, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Animal, Surgery Type, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Animal, Surgery Type, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Animal, Surgery Type, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Zoetis Inc. (Rimadyl, Galliprant)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health (Onsior)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Norbrook Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dechra Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phibro Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kindred Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aratana Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacira Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bimeda Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Huvepharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Associated British Foods
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nexcyon Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VetDC Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torigen Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phibro Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations